.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Novel Approaches in Prostate Cancer Treatment

EP. 1: ADT and Its Consequences in the Treatment of Prostate Cancer

October 25th 2019

EP. 2: Combination Therapy for Localized Prostate Cancer

October 25th 2019

EP. 3: Optimal ADT for Patients With Prostate Cancer and CV History

October 25th 2019

EP. 4: Active Surveillance and Prognostic Value of Prostate Biopsy

October 25th 2019

EP. 5: Early Salvage Radiotherapy for Early Prostate Cancer

October 25th 2019

EP. 6: Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

EP. 7: ARAMIS: Safety and Efficacy of Darolutamide in nmCRPC

October 25th 2019

EP. 8: QOL in Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

EP. 9: Prostate Cancer: PSA-DT and Initiating AR-Targeted Therapy

October 25th 2019

EP. 10: Clinical Phenotypes of Prostate Cancer and Prognostic Factors

October 25th 2019

EP. 11: STAMPEDE: Docetaxel for Hormone-Naive Prostate Cancer

October 25th 2019

EP. 12: Prostate Cancer: Characterize Biologies, Integrate Therapies

October 25th 2019

EP. 13: Triplet vs Doublet Therapy for mCSPC

October 25th 2019

EP. 14: PROfound: Olaparib for HRR+ mCRPC

October 25th 2019

EP. 15: Role of Biomarkers in Metastatic Prostate Cancer

October 25th 2019

EP. 16: CARD: Sequencing Therapies in Metastatic Prostate Cancer

October 25th 2019

EP. 17: Optimal Timing for Radium-223 With AR-Targeted Therapy

October 25th 2019

EP. 18: Final Thoughts on Evolving Treatment of Prostate Cancer

October 25th 2019